The minimal tuberculostatic concentration is 0.025 to 0.05 µg/ml.

The pharmaceutical formulation according to the present invention contains resveratrol, a tuberculostatic agent, and a pharmaceutically acceptable carrier.

In addition, the compound creates a synergistic effect when combined with a conventional tuberculostatic drug, and thus can be more effective for treating tuberculosis.

Patients receive tuberculostatic therapy with one of the drugs of group “A” (highly effective drugs), “B” (fairly effective means) or combined therapy.

Patients receive tuberculostatic therapy with one of the drugs of group “A” (highly effective drugs), “B” (fairly effective means) or combined therapy.